troglitazone has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 2 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tabatabaei Dakhili, SA | 1 |
| Pérez, DJ | 1 |
| Gopal, K | 1 |
| Haque, M | 1 |
| Ussher, JR | 1 |
| Kashfi, K | 1 |
| Velázquez-Martínez, CA | 1 |
| Geoffroy, M | 1 |
| Kleinclauss, A | 1 |
| Grandemange, S | 1 |
| Hupont, S | 1 |
| Boisbrun, M | 1 |
| Flament, S | 1 |
| Grillier-Vuissoz, I | 1 |
| Kuntz, S | 1 |
2 other studies available for troglitazone and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
SP1-independent inhibition of FOXM1 by modified thiazolidinediones.
Topics: Amino Acid Sequence; Antineoplastic Agents; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Dr | 2021 |
Pro-apoptotic effect of Δ2-TGZ in "claudin-1-low" triple-negative breast cancer cells: involvement of claudin-1.
Topics: Antineoplastic Agents; Apoptosis; Caspase 3; Caspase 7; Cell Line, Tumor; Cell Proliferation; Claudi | 2017 |